Literature DB >> 34170432

Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report.

Giorgia T Maniscalco1,2, Lia Allegorico3, Maria Elena Di Battista3,4, Mario Annunziata5, Simona Salvatore4, Valentino Manzo4.   

Abstract

Entities:  

Year:  2021        PMID： 34170432     DOI： 10.1007/s10072-021-05379-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  7 in total

1.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

Authors:  Kieron Dunleavy; Frances Hakim; Hyun Kyung Kim; John E Janik; Nicole Grant; Takayuki Nakayama; Therese White; George Wright; Larry Kwak; Ronald Gress; Giovanna Tosato; Wyndham H Wilson
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

Review 2.  Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.

Authors:  Chiara Zanetta; Micaela Robotti; Agostino Nozzolillo; Francesca Sangalli; Giuseppe Liberatore; Eduardo Nobile-Orazio; Massimo Filippi; Lucia Moiola
Journal:  J Neurol Sci       Date:  2019-11-28       Impact factor: 3.181

3.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

Authors:  Benjamin Terrier; Marc Ittah; Léa Tourneur; Fawzia Louache; Vassili Soumelis; Frédéric Lavie; Nicole Casadevall; Sophie Candon; Aurélie Hummel; Xavier Mariette; Agnès Buzyn
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

4.  Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis.

Authors:  Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Anne Zinganell; Franziska Di Pauli; Paulus Rommer; Florian Deisenhammer; Fritz Leutmezer; Thomas Berger
Journal:  Mult Scler Relat Disord       Date:  2020-07-17       Impact factor: 4.339

Review 5.  Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.

Authors:  William E Monaco; Jonathan D Jones; William F C Rigby
Journal:  Clin Rheumatol       Date:  2016-05-21       Impact factor: 2.980

6.  Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.

Authors:  Gabrielle Macaron; Mary A Willis; Daniel Ontaneda; Hubert Fernandez; Sanghoon Kim; Stephen E Jones; Erik P Pioro; Jeffrey A Cohen
Journal:  Neurology       Date:  2019-12-31       Impact factor: 9.910

7.  Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow.

Authors:  Yoshihiro Ueda; Motonari Kondo; Garnett Kelsoe
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307
  7 in total
  1 in total

1.  Remote smartphone gait monitoring and fall prediction in Parkinson's disease during the COVID-19 lockdown.

Authors:  Massimo Marano; Francesco Motolese; Mariagrazia Rossi; Alessandro Magliozzi; Ziv Yekutieli; Vincenzo Di Lazzaro
Journal:  Neurol Sci       Date:  2021-05-27       Impact factor: 3.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.